Literature DB >> 1571714

Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review.

L Fouillard1, L Mouthon, J P Laporte, F Isnard, J Stachowiak, M Aoudjhane, J C Lucet, M Wolf, F Bricourt, L Douay.   

Abstract

Three patients with acute leukemia who underwent autologous bone marrow transplantation (BMT) in complete remission, developed a severe respiratory syncytial virus (RSV) pneumonia, which was fatal in two. Identification of RSV was made on the products of bronchoalveolar lavage by direct immunofluorescence. As already described by others, the initial course of RSV infection varies, depending on whether it occurs sooner or later after BMT with a better prognosis in the latter situation. Treatment consists of aerosolized ribavirin. Infection by RSV is caused by manual contact with infected persons and contaminated surfaces. The severity of lung RSV infection in the course of BMT suggests the need for prophylactic measures in addition to standard isolation precautions.

Entities:  

Mesh:

Year:  1992        PMID: 1571714

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

2.  Respiratory syncytial virus, a rare cause of severe pneumonia following bone marrow transplantation.

Authors:  J T van Dissel; J M Zijlmans; A C Kroes; W E Fibbe
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

3.  Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Authors:  H Plotnicky-Gilquin; L Goetsch; T Huss; T Champion; A Beck; J F Haeuw; T N Nguyen; J Y Bonnefoy; N Corvaïa; U F Power
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 4.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

Review 5.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Comparison of an immunochromatography test with multiplex reverse transcription-PCR for rapid diagnosis of respiratory syncytial virus infections.

Authors:  Yuki Kuroiwa; Kazushige Nagai; Lisa Okita; Susumu Ukae; Toshihiko Mori; Tomoyuki Hotsubo; Hiroyuki Tsutsumi
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Genetic variability and molecular epidemiology of respiratory syncytial virus subgroup a strains in Japan determined by heteroduplex mobility assay.

Authors:  Yuki Kuroiwa; Kazushige Nagai; Lisa Okita; Hiroyuki Tsutsumi
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 9.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 10.  Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Authors:  Lindsay Broadbent; Helen Groves; Michael D Shields; Ultan F Power
Journal:  Influenza Other Respir Viruses       Date:  2015-07       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.